Co-expression of bfl-1 enhances host response in the herpes simplex virus-thymidine kinase/ganciclovir gene therapy system

Biochemical and Biophysical Research Communications

Volumn 303, Issue 3, 2003, Pages 756-763

  Kwon, Ghee Young ^a   Jeong, Jaehoon ^b   Woo, Jong Kyu ^b   Choi, Hye Young ^b   Lee, Min Jung ^b   Ko, Jae Kyun ^b   Shim, Yhong Hee ^c   Kim, Chul Woo ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

bfl 1; Ganciclovir; Gene therapy; Herpes simplex virus; Thymidine kinase

Indexed keywords

CD40 ANTIGEN; FAS ANTIGEN; GANCICLOVIR; PROTEIN; PROTEIN BCL XL; PROTEIN BFL 1; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; COLON ADENOCARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; TUMOR IMMUNITY; UPREGULATION;

MURINAE; SIMPLEXVIRUS;

EID: 0037432603     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00417-0     Document Type: Article

References (19)

1. Moolten F.L., Wells J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82:1990;297-300.
2. Kun L.E., Gajjar A., Muhlbauer M., Heideman R.L., Sanford R., Brenner M., Walter A., Langston J., Jenkins J., Facchini S. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum. Gene Ther. 6:1995;1231-1255.
3. Smythe W.R. Prodrug/drug sensitivity gene therapy: current status. Curr. Oncol. Rep. 2:2000;17-22.
4. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., Abraham G.N. The "bystander effect:" tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283.
5. Freeman S.M., Whartenby K.A., Freeman J.L., Abboud C.N., Marrogi A.J. In situ use of suicide gene for cancer therapy. Semin. Oncol. 23:1996;31-45.
6. Melcher A., Todryk S., Hardwick N., Ford M., Jacobson M., Vile R. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:1998;581-587.
7. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:1995;399-415.
8. Colombo M.P., Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today. 15:1994;48-51.
9. Soler M.N., Milhaud G., Lekmine F., Treihou-Lahile F., Klatzmann D., Lausson S. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol. Immunother. 48:1999;91-99.
10. Okada H., Giezeman-Smits K.M., Tahara H., Attanucci J., Fellows W.K., Lotze M.T., Chambers W.H., Bozik M.E. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 6:1999;219-226.
11. Hassan W., Sanford M.A., Woo S.L.C., Chen S.-H., Hall S.J. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J. Urol. 18:2000;130-135.
12. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA. 92:1995;4342-4346.
13. Grewal I.S., Flavell R.A. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol. Today. 17:1996;410-414.
14. Propato A., Cutrona G., Francavilla V., Ulivi M., Schiaffella E., Landt O., Dunbar R., Cerundolo V., Ferrarini M., Barnaba V. Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nat. Med. 7:2001;807-813.
15. Zanelli E., Toes R.E. A dual function for CD40 agonists. Nat. Med. 6:2000;629-630.
16. Chiodoni C., Paglia P., Stoppacciaro A., Rodolfo M., Parenza M., Colombo M.P. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190:1999;125-133.
17. Beltinger C., Fulda S., Kammertoens T., Meyer E., Uckert W., Debatin K.-M. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA. 96:1999;8699-8704.
18. Wei S.J., Chao Y., Shih Y.L., Yang D.-M., Hung Y.-M., Yang W.K. Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase. Gene Ther. 6:1999;420-431.
19. Gottlieb R.A. Mitochondria: execution central. FEBS Lett. 482:2000;6-12.